Cutaneous Squamous Cell Carcinoma (cSCC) Market Report 2026

The cutaneous squamous cell carcinoma (cscc) market size has grown strongly in recent years. It will grow from $7.87 billion in 2025 to $8.33 billion in 2026 at a compound annual growth rate (CAGR) of 5.8%. The growth in the historic period can be attributed to high uv exposure rates, aging population growth, increased skin cancer awareness, reliance on surgical excision, hospital-based oncology care.

The cutaneous squamous cell carcinoma (cscc) market size is expected to see strong growth in the next few years. It will grow to $10.35 billion in 2030 at a compound annual growth rate (CAGR) of 5.6%. The growth in the forecast period can be attributed to advancements in skin cancer diagnostics, rising adoption of outpatient procedures, growth of dermatologic oncology centers, improved access to early detection, development of targeted therapies. Major trends in the forecast period include rising adoption of mohs micrographic surgery, increased use of non-surgical therapies, growth of early skin cancer screening, expansion of outpatient cancer treatment, focus on minimally invasive procedures.

The growing awareness of skin cancer is expected to drive the growth of the cutaneous squamous cell carcinoma (cSCC) market in the coming years. Skin cancer involves the abnormal growth of skin cells, often resulting from excessive exposure to ultraviolet radiation, and can range from non-life-threatening conditions to aggressive malignancies. Increased awareness of skin cancer is supported by expanded public health campaigns, better access to medical information, and a stronger focus on early detection and prevention, which together are increasing demand for advanced diagnostic and treatment options. Cutaneous squamous cell carcinoma care supports improved skin cancer management by enabling targeted treatment approaches, enhancing diagnostic accuracy, and improving patient outcomes. For instance, in January 2024, according to the American Cancer Society, a US-based non-profit organization, 104,930 cases of skin cancer were reported in 2023, representing a 3.2% increase compared to 108,270 cases reported in 2022. Therefore, increasing awareness of skin cancer is contributing to the growth of the cutaneous squamous cell carcinoma market.

Major companies operating in the cutaneous squamous cell carcinoma market are focusing on advances in immuno-oncology therapies, including PD-L1 inhibitors and targeted treatment approaches, to improve patient outcomes and provide effective options for managing advanced skin cancer. Programmed death-ligand 1 (PD-L1) is a protein that suppresses immune activity by binding to PD-1 receptors on T-cells, allowing cancer cells to evade immune responses. For example, in December 2024, Checkpoint Therapeutics Inc., a US-based biotechnology company, received approval from the US Food and Drug Administration for Unloxcyt (cosibelimab-ipdl). This therapy works by blocking PD-L1, thereby enhancing the immune system’s ability to attack cancer cells while offering a safer and more effective treatment option. Its dual mechanisms of action present a promising approach for treating advanced cutaneous squamous cell carcinoma. The approval was supported by data from the CK-301-101 clinical trial, which demonstrated clinically meaningful objective response rates and durable responses in patients with advanced cSCC.

In March 2025, Sun Pharmaceutical Industries Limited, an India-based pharmaceutical company, acquired Checkpoint Therapeutics, Inc. for approximately USD 355 million. Through this acquisition, Sun Pharma gained access to Checkpoint’s FDA-approved anti-PD-L1 therapy cosibelimab for the treatment of advanced cutaneous squamous cell carcinoma. This move strengthens Sun Pharma’s oncology portfolio while enhancing its commercial scale and expanding its global therapeutic reach. Checkpoint Therapeutics Inc. is a US-based company specializing in immunotherapy and targeted oncology treatments, with expertise in developing next-generation immune checkpoint inhibitors.

Major companies operating in the cutaneous squamous cell carcinoma (cscc) market are F. Hoffmann-La Roche AG, Merck & Co. Inc., Sanofi S.A., Bristol-Myers Squibb Company, Novartis AG, GSK plc, Eli Lilly and Company, Amgen Inc., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Incyte Corporation, Shanghai Henlius Biotech Inc., Fortress Biotech Inc., Rakuten Medical Inc., Morphogenesis Inc., Vidac Pharma Inc., Pfizer Inc., AstraZeneca plc, AbbVie Inc., Johnson & Johnson, Bayer AG, LEO Pharma A/S, Sun Pharmaceutical Industries Ltd.

North America was the largest region in the cutaneous squamous cell carcinoma (CSCC) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cutaneous squamous cell carcinoma (cscc) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cutaneous squamous cell carcinoma (cscc) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the cutaneous squamous cell carcinoma market by increasing costs of imported diagnostic imaging equipment, surgical instruments, and topical oncology drugs. Cancer institutes and hospitals in North America and Europe are most affected due to reliance on imported devices, while Asia-Pacific faces higher treatment infrastructure costs. These tariffs are increasing procedure expenses. However, they are also encouraging domestic medical device manufacturing and regional oncology innovation.

The cutaneous squamous cell carcinoma (cscc) market research report is one of a series of new reports that provides cutaneous squamous cell carcinoma (cscc) market statistics, including cutaneous squamous cell carcinoma (cscc) industry global market size, regional shares, competitors with a cutaneous squamous cell carcinoma (cscc) market share, detailed cutaneous squamous cell carcinoma (cscc) market segments, market trends and opportunities, and any further data you may need to thrive in the cutaneous squamous cell carcinoma (cscc) industry. This cutaneous squamous cell carcinoma (cscc) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Cutaneous squamous cell carcinoma (cSCC) is a form of skin cancer that arises from the squamous cells located in the outer layer of the skin. It most commonly develops on areas exposed to sunlight and can vary in severity, ranging from localized tumors to more aggressive forms that may spread to other parts of the body.

The primary treatment approaches for cutaneous squamous cell carcinoma include surgical and non-surgical treatments. Surgical options involve removing cancerous tissue through procedures such as standard excision or Mohs micrographic surgery, which aim to completely eliminate the tumor while preserving as much healthy tissue as possible. Diagnostic methods for cSCC include computed tomography (CT), magnetic resonance imaging (MRI), and biopsy, and these procedures are carried out across healthcare settings such as hospitals, cancer institutes, ambulatory surgical centers, and other medical facilities.

The cutaneous squamous cell carcinoma (cSCC) market consists of revenues earned by providing radiation therapy, chemotherapy services, immunotherapy and targeted therapy services, diagnostic services, and follow-up and support services. The market value includes the value of related goods sold by the service provider or included within the service offering. The cutaneous squamous cell carcinoma (CsCC) market also includes sales of topical treatments such as 5-fluorouracil, imiquimod, monoclonal antibodies, and vaccines. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.